Cellartis, Novo Nordisk and Lund University to research diabetes treatment using embryonic stem cells

Thursday 30 October 2008

A long-standing collaboration among Cellartis AB, the Hagedorn Research Institute of Novo Nordisk, and Professor Henrik Semb of Lund University into diabetes has been upgraded with a view to developing a new cell therapy for the treatment of type 1 diabetes.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Sweden